Search | Clinical Trials Finder

Conditions: Clostridium Difficile Infection
Interventions: SER-262, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more

Conditions: Dental Pain
Interventions: Pre-Op pregabalin, Pre-Op Placebo 1, Post-Op pregabalin, Post-Op Placebo 1, Post-Op Placebo 2, Post-Op acetaminophen; Drug
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 17 Years to 55 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Bupropion, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort C: bevacizumab, Cohort C: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Coccidioidomycosis
Interventions: nikkomycin Z, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Breast Cancer
Interventions: Fulvestrant, GDC-0941, GDC-0941 Matching Placebo, GDC-0980, GDC-0980 Matching Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Hayward, California • Oakland, California + 35 more

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Lung Inflammation
Interventions: placebo pill and placebo IV, Lovastatin pill and placebo IV, placebo pill and recombinant human activated protein C IV, Endotoxin; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 19 Years to 44 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 98
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more

Conditions: Acute Myeloid Leukemia
Interventions: Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more

Conditions: HIV Infections
Interventions: Chloroquine, Placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more

Conditions: Bipolar Disorder
Interventions: Placebo, Aripiprazole, Haloperidol; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Anaheim, California • Cerritos, California • Garden Grove, California + 12 more

Conditions: Hypotension, Pregnancy
Interventions: ondansetron, placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more

Conditions: Functional Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Months to 23 Months
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more

Conditions: Healthy
Interventions: Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hepatitis C
Interventions: TMC435, TVR; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 32
States / cities: Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more

Conditions: Schizophrenia
Interventions: MK-8189, Placebo, Background AAP Therapy; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Metastatic Colorectal Cancer
Interventions: FOLFIRI, AMG 655, Placebo, AMG 479; Other · Biological
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 28
States / cities: Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Cognitive Remediation, Computer Games; Behavioral
Lead sponsor: Wesleyan University; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Hartford, Connecticut • Middletown, Connecticut

Conditions: Healthy Participants, Obesity
Interventions: AZD1043, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Search by objective public record fields.

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Dental Pain Study of Analgesics in Patients Undergoing Molar Removal

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Quantifying Airway Inflammation With Radiologic Tests

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

Study of Aripiprazole in Patients With Acute Bipolar Mania

Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

A Study of the Cardiac Effects of Danicopan in Healthy Adults

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Comparing Cognitive Remediation Approaches for Schizophrenia

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.